Table 6.
Combination treatment changes and discontinuation during follow-up.
| Total post-index, per patient (N = 148) | |
|---|---|
| Follow-up (days) | |
| Mean (SD) | 207.1 (121.1) |
| Median (range) | 224.5 (0–485) |
| Any discontinuation (onabotA or mAb), n (%) | 90 (60.8%) |
| Discontinuation of onabotA therapy, n (%) | 42 (28.2%) |
| Follow-up duration until discontinuation (days) | |
| Mean (SD) | 132.1 (110.2) |
| Median (range) | 101 (0–340) |
| Reason for discontinuation a , n (%) | |
| Lack of effect | 16 (38.1%) |
| Lack of insurance coverage | 12 (28.6%) |
| Analysis derivedb | 12 (28.6%) |
| Other/unknown | 2 (4.8%) |
| Discontinuation of mAb therapy, n (%) | 50 (33.8%) |
| Follow-up duration until discontinuation (days) | |
| Mean (SD) | 185.0 (96.9) |
| Median (range) | 177.5 (44–392) |
| Reason for discontinuation a , n (%) | |
| Lack of effect | 15 (30%) |
| Lack of insurance coverage | 25 (50%) |
| Safety/tolerability | 7 (14%) |
| Other/unknown | 4 (8%) |
| Change in mAb brandc, n (%) | 19 (12.8%) |
| Number of changes in mAb brand during follow-up, median (range) | 1.0 (1–1) |
| Change of mAb dosec, n (%) | 11 (7.4%) |
| Number of changes in mAb dose during follow-up, median (range) | 1.0 (1–1) |
| Change of mAb regimen, n (%) | |
| No | 148 (100%) |
aMultiple reasons for discontinuation were allowed and therefore may not sum to 100%.
bPatients were considered to discontinue onabotA if consecutive injections occurred >24 weeks apart.
cIndicates patient had at least one change in mAb brand/dose/regimen.